Citius Oncology, Inc. (CTOR)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
$0.66
-4.18%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$61.7M
Shares Outstanding
93.0M
P/S (TTM)
11.0x
Exchange
NCM
Currency
USD
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3.9M | 1.7M |
| Gross Profit | 3.2M | 1.3M | ||
| Operating Income | -4.9M | -4.7M | -5.3M | -28.6M |
| Net Income | -5.4M | -5.0M | -5.5M | -26.6M |
| Diluted EPS | $-0.08 | $nan | $-0.06 | $-0.27 |
Annual Financials
| Metric | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.9M | -12.1M | -20.6M | -23.5M |
| Net Income | -5.4M | -12.7M | -21.1M | -24.8M |
| Diluted EPS | $-0.08 | $-0.18 | $-0.31 | $-0.34 |